Sean A. McCarthy sold $462k of CTMX
CEO at CytomX Therapeutics, Inc.. 101,793 shares at an average of $4.54, traded Nov 6, 2025, filed Nov 10, 2025.
Score components
- +25RoleCEO
- +17Trade size$462k at market
- 0Share of holdings soldSold 9.3% of holdings
- 0ClusterNo other insider selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -6.9%, 3m +36.0%, 6m -7.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001610717-25-000372, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 6, 2025 | SOpen-market sale Class A Common Stock10b5-1 | -101,793 | $4.54 | $462k | 987,891 | Nov 10, 2025 |
Related signals
Other insiders at CytomX Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | CTMXsell CytomX Therapeutics, Inc. | Christopher Ogden Chief Financial Officer | $4,953 1,624 shares | -1% | |
| 42Moderate | CytomX Therapeutics, Inc. | Marcia Belvin SVP, Chief Scientific Officer | $202k 31,492 shares | -9% | |
| 46Moderate | CytomX Therapeutics, Inc. | Yu-Waye Chu Chief Medical Officer | $137k 21,279 shares | -10% | |
| 47Moderate | CytomX Therapeutics, Inc. | Christopher Ogden Chief Financial Officer | $124k 19,323 shares | -6% | |
| 42Moderate | CytomX Therapeutics, Inc. | Sean A. McCarthy CEO | $764k 118,969 shares | -10% | |
| 21Weak | CytomX Therapeutics, Inc. | Marcia Belvin SVP, Chief Scientific Officer | $37k 13,884 shares | -5% | |
| 36Weak | CytomX Therapeutics, Inc. | Sean A. McCarthy CEO | $149k 55,511 shares | -5% | |
| 28Weak | CytomX Therapeutics, Inc. | Christopher Ogden Chief Financial Officer | $33k 12,255 shares | -6% | |
| 30Weak | CytomX Therapeutics, Inc. | Marcia Belvin SVP, Chief Scientific Officer | $12k 19,512 shares | -7% | |
| 30Weak | CytomX Therapeutics, Inc. | Yu-Waye Chu Chief Medical Officer | $2,411 4,025 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.